{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "f35e443bbf8242ccddc7c3ae3c14185f",
    "title": "Market Insights | Markets | Equities + AstraZeneca (BUY) - Progress on Baxdrostat 10% sales at peak) important for confidence -",
    "source_uri": "25.9月 普通个人版/9.1 普通个人版/GS/AstraZeneca (BUY) - Progress on Baxdrostat (10% sales at peak) important for confidence -_2025-09-01",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T11:46:36.548643",
      "extracted_at": "2025-10-26T11:46:36.548651"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 4,
        "successful_pages": 4,
        "date": "2025-09-01",
        "publication": "25.9月 普通个人版/9.1 普通个人版/GS",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 0,
          "removed_paragraphs": 3,
          "reduction_ratio": 0.029906226239756695
        },
        "input_relative_path": "25.9月 普通个人版/9.1 普通个人版/GS"
      }
    }
  },
  "passages": [
    {
      "passage_id": "63f259294d6126dd",
      "text": "AZN has often been considered the best pharma name you can own in Europe. Specialists like it and YTD has indeed remained the 2 best performer within large cap pharma behind NOvN. This remains a core name to own as the traiectov on their high profile new drug for hypertension (Baxdrostat) looks promising. This is a drug that, according to AZN, might represent \\(\\) 5bn\\(- or \\sim 10\\%\\) of 2024 sales - at peak. Delivery & success of Baxdo would increase confidence in AZN ability to deliver on top- line growth.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "9f2532c9327b1aa7",
      "text": "Even by multiple alone, delivery on this should warrant a 20x P/E multiple vs current \\(5mmHg significantly lower the risk of major cardiovascular events, so above numbers might imply a double-digit decrease in the % of strokes/heart failure and all-cause mortality.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "dfafd083de195753",
      "text": "- More compelling for doctors to prescribe: As Baxdo and lourdostrat have similar mmHg reduction profile, Baxdo importantly showed no clinically",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "5ab5e0ab26ce6af6",
      "text": "meaningful drug- drug interaction, which is a differentiator vs lorundostrat. The 24- hour and nighttime blood pressure control data were another differentiator, supported by longer half- life results: (26 to 31 hours for baxdrostat vs. 10 to 12 hours for lorundrostat). For reference \"half- life\" means the time it requires for a drug to halve its concentration (so longer it' s better).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b316f0b1135d6a18",
      "text": "- AZN better distribution and faster timeline to commercialization: Minerals who is developing lorundostrat is a \\(1b\\) market cap company, hence - barring any acquisition - has less distribution capabilities for the time being. AZN management noted in the US, c. 85% of 2L+ hypertension patients (i.e. those that require more than 2 dose of medications to manage blood pressure) are managed by primary care physicians and specialists, 90% of whom are currently covered by AZN' s CVRM teams. In ex-US markets, where management sees significant commercial potential, AZN' s presence was highlighted with Farxiga and Lokelma sold in 115+ countries. On launch timelines, management expect filing by 2025 year-end and launch in the US in 2026, likely resulting in baxdrostat launching earlier than lorundrostat.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "0164ef917a9969e9",
      "text": "Edoardo L. Greco  Executive Director - Franchise Sales  Global Banking & Markets - Equities Division - Goldman Sachs International  +44 (0) 20 7051 1594 - 25 Shoe Lane - EC4A 4AU - London - United Kingdom",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "5d7e8c53e15fe6be",
      "text": "When this document is disseminated in Australia by Goldman Sachs & Co. LLC (\"GSCO\"), Goldman Sachs International (\"GSI\"), Goldman Sachs (Asia) L.L.C. (\"GSALLC\") or Goldman Sachs (Singapore) Pte (\"GSSP\") (collectively the \"GS entities\"), this document, and any access to it, is intended only for a person that has first satisfied the GS entities that:",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "dbb05bccf5e81a73",
      "text": "- the person is a sophisticated or Professional Investor for the purposes of section 708 of the Corporations Act of Australia; and- the person is a wholesale client for the purpose of section 761G of the Corporations Act of Australia.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4b6d2a250ce2d255",
      "text": "To the extent that the GS entities are providing a financial service in Australia, the GS entities are each exempt from the requirement to hold an Australian financial services licence for the financial services they provide in Australia. Each of the GS entities are regulated by a foreign regulator under foreign laws w which differ from Australian laws, specifically:",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "9ffc6ebe5ad57f10",
      "text": "- GSCO is regulated by the US Securities and Exchange Commission under US laws; \n- GSI is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, under UK law s; \n- GSALLC is regulated by the Hong Kong Securities and Futures Commission under Hong Kong law s; and \n- GSSP is regulated by the Monetary Authority of Singapore under Singapore law s.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f2b38e1ae30b0eda",
      "text": "Marquee is not meant for the general public in Brazil. The services or products provided by or through Marquee may not be offered or sold to the general public in Brazil. You have received a passw ord granting access to Marquee exclusively due to your existing relationship with a GS business located in Brazil. The selection and engagement with any of the offered services or products through Marquee w ill be carried out directly by you. Before acting to implement any chosen service or products, provided by or through Marquee",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "25e56395f1b46e96",
      "text": "you should consider, at your sole discretion, w hether it is suitable for your particular circumstances and, if necessary, seek professional advice. Any steps necessary in order to implement the chosen service or product, including but not limited to remittance of funds, shall be carried out at your discretion. Accordingly, such services and products have not been and will not be publicly issued, placed, distributed, offered or negotiated in the Brazilian capital market, and, as a result, they have not been and will not be registered w ith the Brazilian Securities Commission (Comissao de Valores Mobiliarios), nor have they been submitted to the foregoing agency for approval. Documents relating to such services or products, as well as the information contained therein, may not be supplied to the general public in Brazil, as the offering of such services or products is not a public offering in Brazil, nor used in connection with any offer for subscription or sale of securities to the general public in Brazil.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "9abb2c4a5ffb7679",
      "text": "The offer of any securities mentioned in this message may not be made to the general public in Brazil. Accordingly, any such securities have not been nor w ill they be registered with the Brazilian Securities Commission (Comissão de Valores Mobiliários) nor has any offer been submitted to the foregoing agency for approval. Documents relating to the offer, as w ell as the information contained therein, may not be supplied to the public in Brazil, as the offer is not a public offering of securities in Brazil.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b46d736f2cdb4d14",
      "text": "Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9hs às 18hs.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "7cd4f841e999745c",
      "text": "Available Weekdays (except holidays), from 9 am to 6 pm.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "ef9e9891f3f22308",
      "text": "Standard & Poor's ® and S&P ® are registered trademarks of The McGraw-Hill Companies, Inc. and S&P GSCI™ is a trademark of The McGraw-Hill Companies, Inc. and have been licensed for use by the Issuer. This Product (the \"Product\") is not sponsored, endorsed, sold or promoted by S&P and S&P makes no representation, w arranty or condition regarding the advisability of investing in the Product.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "be3e43afeb1804ff",
      "text": "Notice to Investors in the European Economic Area",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f4d1b00b76a6acce",
      "text": "Marquee is made available in the European Economic Area by Goldman Sachs International.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "207fb7b0bab8e144",
      "text": "Notice to Investors in Korea",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "e8561558beeedd15",
      "text": "Marquee is made available in Korea by Goldman Sachs (Asia) L.L.C. Seoul Branch.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "89219d9be7a95397",
      "text": "Notice to Investors in Japan",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c6b1eba8c01732cd",
      "text": "Marquee is made available in Japan by Goldman Sachs Japan Co., Ltd.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "65c715dd4aa1eb33",
      "text": "本書は情報の提供を目的としております。また、売却・購入が違法となるような法域での有価証券その他の売却若しくは購入を勧めるものでもありません。ゴールドマン・サックスは本書内の取引又はストラクチャーの勧誘を行うものではございません。これらの取引又はストラクチャーは、社内及び法規制等の承認等次第で実際にはご提供できない場合がございます。",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "44419908ff1c922b",
      "text": "本資料は、適格機関投資家のお客さまのみを対象に作成されたものです。本資料における金融商品は適格機関投資家のお客さまのみがお取引可能であり、適格機関投資家以外のお客さまからのご注文等はお受けできませんので、ご注意ください。商号等/ゴールドマン・サックス証券株式会社 金融商品取引業者 関東財務局長（金商）第６９号 加入協会/ 日本証券業協会、一般社団法人金融先物取引業協会、一般社団法人第二種金融商品取引業協会",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5fa9e54838846bfd",
      "text": "ゴールドマン・サックス証券株式会社が適格機関投資家のみを相手方として取得申込みの勧誘（取得勧誘）又は売付けの申込み若しくは買付けの申込みの勧誘(売付け勧誘等)を行う本有価証券には、適格機関投資家に譲渡する場合以外の譲渡が禁止される旨の制限が付されています。本有価証券は金融商品取引法第４条に基づく財務局に対する届出が行われておりません。なお、本告知はお客様によるご同意のもとに、電磁的に交付させていただいております。",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "dda40ebe0be49d24",
      "text": "本書又はその添付資料に信用格付が記載されている場合、日本格付研究所（JCR）及び格付投資情報センター（R&I）による格付は、登録信用格付業者による格付（登録格付）です。その他の格付は登録格付である旨の記載がない場合は、無登録格付です。無登録格付を投資判断に利用する前に、「無登録格付に関する説明書」（http://w w w .goldmansachs.com/disclaimer/ratings.html）を十分にお読みください。",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "dcf4c02be4d933ad",
      "text": "If any credit ratings are contained in this material or any attachments, those that have been issued by Japan Credit Rating Agency, Ltd. (JCR) or Rating and Investment Information, Inc. (R&I) are credit ratings that have been issued by a credit rating agency registered in Japan (registered credit ratings). Other credit ratings are unregistered unless denoted as being registered. Before using unregistered credit ratings to make investment decisions, please carefully read \"Explanation Regarding Unregistered Credit Ratings\" (http://w w w .goldmansachs.com/disclaimer/ratings.html).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "d8db556491847587",
      "text": "Notice to Investors in New Zealand",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "31dfebdbdf5cc270",
      "text": "When this document is disseminated in New Zealand by Goldman Sachs & Co. LLC (\"GSCO\"), Goldman Sachs International (\"GSF\"), Goldman Sachs (Asia) L.L.C. (\"GSALLC\") or Goldman Sachs (Singapore) Pte (\"GSSP\") (collectively the \"GS entities\"), this document, and any access to it, is intended only for a person that has first satisfied the GS entities that the person is someone:",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "37d81f82f6b3deed",
      "text": "(i) w ho is an investment business w ithin the meaning of clause 37 of Schedule 1 of the Financial Markets Conduct Act 2013 (New Zealand) (the \"FMCAct\"); (ii) w ho meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMCAct; (iii) w ho is large w ithin the meaning of clause 39 of Schedule 1 of the FMCAct; or (iv) is a government agency w ithin the meaning of clause 40 of Schedule 1 of the FMCAct.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "c1b101eaa194d219",
      "text": "No offer to acquire the interests is being made to you in this document. Any offer w ill only be made in circumstances w here disclosure is not required under the Financial Markets Conducts Act 2013 or the Financial Markets Conduct Regulations 2014.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "be945f610c727731",
      "text": "Notice to Investors in Switzerland",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "2493961b27a4ea9a",
      "text": "Marquee is made available in Switzerland by Goldman Sachs International.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "ad0112fcd18c5467",
      "text": "\\(①\\) Copyright 2002- 2025 Goldman Sachs All rights reserved.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "8472fad97aaa9f2c",
      "text": "Contact us if you have any feedback / comments.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9146425884793473",
      "text": "Use of this site is subject to the Terms and Conditions of Use updated as of 12 August 2024.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "ae02bca1f0d4ba24",
      "text": "Marquee Regulatory Disclosures",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "f147372ce77a6112",
      "text": "Important Disclosure Information About Goldman Sachs Research",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9f70e050401fd353",
      "text": "Please review our Interest Rate Benchmark Transition Notice, Privacy & Cookies Policy, Security, Market Data Attribution, Security Guidance and GS&Co.'s Statement of Financial Condition",
      "page": 3,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "d36f1109e714a3c4",
      "name": "About Goldman",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3d04125be9722532",
      "name": "Additional Disclaimers",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c481df660b904e25",
      "name": "Area\n\nMarquee",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "71ffe2289ed0d84d",
      "name": "As Baxdo",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2377ece5230c67de",
      "name": "Australian Investors",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "9e0b33074ec75b0f",
      "name": "Available Weekdays",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "3066e95bb83f47d9",
      "name": "Benchmark Transition",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "1cf3b52c17d67faf",
      "name": "Blood Pressure",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "916ec28be5b2bd09",
      "name": "Brazilian Investors",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cc653b573dcf08db",
      "name": "Brazilian Securities",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "88f494f365f0299b",
      "name": "Conduct Act",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "900eef27df0b5958",
      "name": "Conduct Regulations",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5678d1059276a82b",
      "name": "Conducts Act",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d0363ae7300e90fb",
      "name": "Cookies Policy",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "cf7454fe4270253d",
      "name": "Corporations Act",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f544bf8c2fcbb21c",
      "name": "Disclosure Information",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d0c63d5ad1856686",
      "name": "Disclosures\n\nImportant",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c1e660e67130c92c",
      "name": "Equities Division",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "21bc9aa97d2d9364",
      "name": "European Economic",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bdc1794badc87d5e",
      "name": "European Society",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "bar",
        "title": "C",
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": []
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "C",
            "unit": null,
            "values": [
              100
            ]
          }
        ],
        "figure_id": "f4b401e3f8d0079a",
        "provenance": {
          "page": 3
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "1ccee54cebe7ae57",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "# Market Insights | Markets | Equities + AstraZeneca (BUY) - Progress on Baxdrostat 10% sales at peak) important for confidence - AZN has often been considered the best pharma name you c",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e3abe5a61ec96089",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ". Even by multiple alone, delivery on this should warrant a 20x P/E multiple vs current \\(< 18x\\) (10% upside) and even more when you consider that GSR has 25% upside with a 8% WACC in their 50/50 DCF",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "43bcf73ccb402138",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t a 20x P/E multiple vs current \\(< 18x\\) (10% upside) and even more when you consider that GSR has 25% upside with a 8% WACC in their 50/50 DCF- P/E based valuation model. ## WHAT YOU NEED TO KNOW AS",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8e1b2e1d63ecd5b4",
        "value": 0.08,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "le vs current \\(< 18x\\) (10% upside) and even more when you consider that GSR has 25% upside with a 8% WACC in their 50/50 DCF- P/E based valuation model. ## WHAT YOU NEED TO KNOW AS A GENERALIST - Th",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "4630c63f5c8fd61e",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tat is one of the most promising drugs for hypertension, where AZN expects \\(\\) 5bn\\(of peak sales (10% of 2024 total sales, that were\\) \\ \\(54b\\) ), \\(50\\%\\) for the drug stand alone and \\(50\\%\\) in ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8db3c7e9aa7a8ee3",
        "value": 0.85,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "isition - has less distribution capabilities for the time being. AZN management noted in the US, c. 85% of 2L+ hypertension patients (i.e. those that require more than 2 dose of medications to manage ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "032258a5be33d33a",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "se of medications to manage blood pressure) are managed by primary care physicians and specialists, 90% of whom are currently covered by AZN' s CVRM teams. In ex-US markets, where management sees sign",
        "provenance": {
          "page": 1
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 1,
      "tables_count": 0,
      "numerical_data_count": 7,
      "passages_count": 39,
      "entities_count": 20
    }
  }
}